Gene Sequencing for EGFR Positive Lung Cancer
(EGFR Lung Canc Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores gene sequencing to better understand EGFR-positive lung cancer. Researchers aim to use a new model to predict who might be at risk for this type of lung cancer by examining specific gene patterns. Blood samples are needed from two groups: women diagnosed with EGFR-positive lung cancer and healthy women with no cancer diagnosis. Participants should either have EGFR-positive lung cancer or be completely healthy without any cancer. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to early detection and prevention strategies for lung cancer.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that utilizing long-read sequencing is safe?
Research has shown that the method used in this study, called long-read sequencing, is generally easy for participants to handle. This technique effectively identifies complex DNA changes that other methods might miss. Many studies have used it without major reports of problems from the sequencing itself. However, these studies primarily assess the accuracy and effectiveness of the sequencing, rather than focusing on safety. Since long-read sequencing is neither a drug nor a procedure that involves entering the body, it typically presents fewer safety concerns than standard medical treatments.12345
Why are researchers excited about this trial?
Researchers are excited about using long-read sequencing for EGFR positive lung cancer because it offers a more detailed view of genetic mutations compared to current methods. Unlike standard treatments that typically focus on targeting the EGFR protein itself, this sequencing technique allows for a comprehensive analysis of the tumor's entire genetic makeup. This approach could lead to more personalized and effective treatment strategies by identifying rare mutations and resistance mechanisms that other methods might miss. By providing a deeper understanding of the cancer's genetic profile, long-read sequencing has the potential to significantly improve patient outcomes.
What evidence suggests that utilizing long-read sequencing is effective for assessing EGFR positive lung cancer?
Research has shown that a new technology called long-read sequencing can effectively study the complex genetic makeup of a type of lung cancer known as EGFR positive. In earlier studies, this method identified important genetic changes in lung cancer patients, which are key to understanding and predicting cancer development. In this trial, researchers will study participants with EGFR positive lung cancer using long-read sequencing to identify these genetic changes. This technology holds promise for predicting cancer risk and creating personalized treatments based on an individual's genetic information. Overall, evidence supports its ability to provide detailed insights into the genetic factors of EGFR positive lung cancer.46789
Are You a Good Fit for This Trial?
This trial is for individuals with non-small cell lung cancer that have EGFR gene mutations, as well as healthy volunteers. The goal is to compare their blood samples and genetic information.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Blood samples are collected from participants for gene sequencing analysis
Data Analysis
Gene sequences are analyzed to validate the risk assessment model
Follow-up
Participants are monitored for any updates or additional data collection needs
What Are the Treatments Tested in This Trial?
Interventions
- Utilizing Long-read Sequencing
Find a Clinic Near You
Who Is Running the Clinical Trial?
Our Lady of the Lake Hospital
Lead Sponsor